Conference Coverage
Conference Coverage
Fitusiran is reversible during dosing suspension
PRAGUE – Temporary suspension of a phase 2 trial of fitusiran offered a chance to study the reversibility of the antithrombin agent.
Conference Coverage
Fund projects, not people to address gender bias in research funding
LONDON – Female investigators are less likely to secure research funding than men simply because they are women, according to research published...
Conference Coverage
Inhibitor risk nears zero after 75 days in previously untreated hemophilia A
PRAGUE – The researchers recommended frequent inhibitor testing until 75 days.
Conference Coverage
Hemophilia intracranial hemorrhage rates declining
PRAGUE – But patients with severe hemophilia face an increased risk of the complication.
Conference Coverage
Survival of patients with mCRPC on hormone therapy differs by race
SAN FRANCISCO – An analysis of male veterans finds that African American men with chemotherapy-naive mCRPC treated with abiraterone or...
Conference Coverage
Pembrolizumab-axitinib nearly halves risk of death in RCC
SAN FRANCISCO – Pembrolizumab and axitinib combination therapy netted superior progression-free and overall survival relative to sunitinib in...
Conference Coverage
Radioligand is highly active in metastatic castrate-resistant prostate cancer
SAN FRANCISCO – Lutetium-177 PSMA-617 (LuPSMA) netted a high rate of PSA response and impressive overall survival among patients who had run out...
Conference Coverage
Pancreatic cancer expression signature is linked to chemoresistance
SAN FRANCISCO – Whole-genome and RNA sequencing of pancreatic cancers in the COMPASS trial has tied an RNA expression signature to poorer survival...
Conference Coverage
Characteristics of mucinous adenocarcinoma highlighted
CORONADO, CALIF. – The condition most commonly presents on the eyelid (29.8%), skin of the face (22.6%), and the skin of the scalp and neck (12.2...
Conference Coverage
PD-1 blockade plus CD19 CAR T boosts CAR T-cell persistence
SAN DIEGO – The combination appears to bolster CAR T-cell effects and persistence in children with relapsed B-ALL.
Conference Coverage
ADT harms likely limited to men with CV comorbidities
WASHINGTON – Androgen deprivation therapy improves survival for men with high-risk cancers, but those with comorbid cardiovascular disease may be...